Organon & Co. (OGN) – What Are Brokerages Saying About This Stock?

Organon & Co. (NYSE:OGN) has earned an average rating of “Reduce” from the seven research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $11.40.

Separately, Weiss Ratings raised Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th.

Institutional Investors Weigh In On Organon & Co.

Hedge funds have recently modified their holdings of the stock. Allied Private Wealth LLC bought a new stake in Organon & Co. in the 2nd quarter valued at about $33,000. Nykredit A S purchased a new stake in shares of Organon & Co. during the second quarter worth $76,000. GAMMA Investing LLC boosted its holdings in shares of Organon & Co. by 69.8% in the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after acquiring an additional 2,376 shares during the period. Wedmont Private Capital bought a new position in shares of Organon & Co. in the second quarter worth $136,000. Finally, Ethic Inc. purchased a new position in shares of Organon & Co. in the third quarter valued at $141,000. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

OGN stock traded up $0.04 during midday trading on Friday, reaching $13.84. 3,947,167 shares of the stock were exchanged, compared to its average volume of 2,241,068. The company has a debt-to-equity ratio of 7.11, a current ratio of 2.02 and a quick ratio of 1.44. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.88. The company has a fifty day moving average price of $13.75 and a 200 day moving average price of $11.60. The stock has a market capitalization of $3.63 billion, a PE ratio of 18.20, a P/E/G ratio of 1.27 and a beta of 1.53.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.06. The company had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.58 billion. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. As a group, analysts expect that Organon & Co. will post 3.24 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Monday, November 9th will be given a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, November 9th. Organon & Co.’s dividend payout ratio (DPR) is presently 10.53%.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.